vs
STANDARD BIOTOOLS INC.（LAB）与Red Violet, Inc.（RDVT）财务数据对比。点击上方公司名可切换其他公司
Red Violet, Inc.的季度营收约是STANDARD BIOTOOLS INC.的1.2倍（$23.4M vs $19.6M），Red Violet, Inc.净利率更高（12.0% vs -177.4%，领先189.4%），Red Violet, Inc.同比增速更快（19.6% vs -11.5%），Red Violet, Inc.自由现金流更多（$6.6M vs $-23.1M），过去两年Red Violet, Inc.的营收复合增速更高（15.6% vs -12.2%）
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
Red Violet, Inc.是一家专注于高级数据分析、风险缓释与身份验证解决方案的科技企业，服务覆盖执法、金融服务、保险、企业合规等多个领域，通过整合公开及专有数据集为客户提供可落地的决策参考洞察。
LAB vs RDVT — 直观对比
营收规模更大
RDVT
是对方的1.2倍
$19.6M
营收增速更快
RDVT
高出31.0%
-11.5%
净利率更高
RDVT
高出189.4%
-177.4%
自由现金流更多
RDVT
多$29.7M
$-23.1M
两年增速更快
RDVT
近两年复合增速
-12.2%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $19.6M | $23.4M |
| 净利润 | $-34.7M | $2.8M |
| 毛利率 | 48.5% | — |
| 营业利润率 | -168.5% | 6.8% |
| 净利率 | -177.4% | 12.0% |
| 营收同比 | -11.5% | 19.6% |
| 净利润同比 | -28.8% | 226.2% |
| 每股收益（稀释后） | $-0.09 | $0.20 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LABRDVT
| Q4 25 | — | $23.4M | ||
| Q3 25 | $19.6M | $23.1M | ||
| Q2 25 | $21.8M | $21.8M | ||
| Q1 25 | $40.8M | $22.0M | ||
| Q4 24 | — | $19.6M | ||
| Q3 24 | $22.1M | $19.1M | ||
| Q2 24 | $22.5M | $19.1M | ||
| Q1 24 | $45.5M | $17.5M |
净利润LABRDVT
| Q4 25 | — | $2.8M | ||
| Q3 25 | $-34.7M | $4.2M | ||
| Q2 25 | $-33.5M | $2.7M | ||
| Q1 25 | $-26.0M | $3.4M | ||
| Q4 24 | — | $863.0K | ||
| Q3 24 | $-26.9M | $1.7M | ||
| Q2 24 | $-45.7M | $2.6M | ||
| Q1 24 | $-32.2M | $1.8M |
毛利率LABRDVT
| Q4 25 | — | — | ||
| Q3 25 | 48.5% | — | ||
| Q2 25 | 48.8% | — | ||
| Q1 25 | 48.4% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 54.9% | — | ||
| Q2 24 | 46.1% | — | ||
| Q1 24 | 53.1% | — |
营业利润率LABRDVT
| Q4 25 | — | 6.8% | ||
| Q3 25 | -168.5% | 19.8% | ||
| Q2 25 | -118.1% | 12.6% | ||
| Q1 25 | -80.8% | 19.1% | ||
| Q4 24 | — | 1.9% | ||
| Q3 24 | -120.9% | 13.1% | ||
| Q2 24 | -134.5% | 16.1% | ||
| Q1 24 | -132.2% | 11.3% |
净利率LABRDVT
| Q4 25 | — | 12.0% | ||
| Q3 25 | -177.4% | 18.3% | ||
| Q2 25 | -153.7% | 12.3% | ||
| Q1 25 | -63.8% | 15.6% | ||
| Q4 24 | — | 4.4% | ||
| Q3 24 | -122.0% | 9.0% | ||
| Q2 24 | -203.3% | 13.8% | ||
| Q1 24 | -70.6% | 10.2% |
每股收益（稀释后）LABRDVT
| Q4 25 | — | $0.20 | ||
| Q3 25 | $-0.09 | $0.29 | ||
| Q2 25 | $-0.09 | $0.18 | ||
| Q1 25 | $-0.07 | $0.24 | ||
| Q4 24 | — | $0.06 | ||
| Q3 24 | $-0.07 | $0.12 | ||
| Q2 24 | $-0.12 | $0.19 | ||
| Q1 24 | $-0.27 | $0.13 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $129.4M | $43.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $399.7M | $100.9M |
| 总资产 | $539.6M | $112.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LABRDVT
| Q4 25 | — | $43.6M | ||
| Q3 25 | $129.4M | $45.4M | ||
| Q2 25 | $158.6M | $38.8M | ||
| Q1 25 | $150.9M | $34.6M | ||
| Q4 24 | — | $36.5M | ||
| Q3 24 | $210.6M | $35.7M | ||
| Q2 24 | $269.8M | $30.9M | ||
| Q1 24 | $287.1M | $32.1M |
总债务LABRDVT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $55.2M | — | ||
| Q2 24 | $55.1M | — | ||
| Q1 24 | $55.0M | — |
股东权益LABRDVT
| Q4 25 | — | $100.9M | ||
| Q3 25 | $399.7M | $101.7M | ||
| Q2 25 | $424.5M | $96.2M | ||
| Q1 25 | $454.6M | $91.8M | ||
| Q4 24 | — | $86.6M | ||
| Q3 24 | $489.3M | $91.7M | ||
| Q2 24 | $510.3M | $88.0M | ||
| Q1 24 | $577.3M | $83.8M |
总资产LABRDVT
| Q4 25 | — | $112.0M | ||
| Q3 25 | $539.6M | $112.1M | ||
| Q2 25 | $557.0M | $104.8M | ||
| Q1 25 | $579.6M | $99.1M | ||
| Q4 24 | — | $98.5M | ||
| Q3 24 | $681.5M | $98.0M | ||
| Q2 24 | $708.7M | $93.5M | ||
| Q1 24 | $777.7M | $94.0M |
负债/权益比LABRDVT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.11× | — | ||
| Q2 24 | 0.11× | — | ||
| Q1 24 | 0.10× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.2M | $6.7M |
| 自由现金流经营现金流 - 资本支出 | $-23.1M | $6.6M |
| 自由现金流率自由现金流/营收 | -118.1% | 28.1% |
| 资本支出强度资本支出/营收 | 4.5% | 0.5% |
| 现金转化率经营现金流/净利润 | — | 2.38× |
| 过去12个月自由现金流最近4个季度 | $-111.1M | $28.8M |
8季度趋势，按日历期对齐
经营现金流LABRDVT
| Q4 25 | — | $6.7M | ||
| Q3 25 | $-22.2M | $10.2M | ||
| Q2 25 | $-20.7M | $7.5M | ||
| Q1 25 | $-30.3M | $5.0M | ||
| Q4 24 | — | $6.7M | ||
| Q3 24 | $-27.9M | $7.2M | ||
| Q2 24 | $-39.0M | $5.7M | ||
| Q1 24 | $-62.5M | $4.3M |
自由现金流LABRDVT
| Q4 25 | — | $6.6M | ||
| Q3 25 | $-23.1M | $10.0M | ||
| Q2 25 | $-22.6M | $7.3M | ||
| Q1 25 | $-35.3M | $5.0M | ||
| Q4 24 | — | $6.7M | ||
| Q3 24 | $-30.1M | $7.2M | ||
| Q2 24 | $-41.0M | $5.7M | ||
| Q1 24 | $-63.3M | $4.2M |
自由现金流率LABRDVT
| Q4 25 | — | 28.1% | ||
| Q3 25 | -118.1% | 43.3% | ||
| Q2 25 | -103.6% | 33.5% | ||
| Q1 25 | -86.6% | 22.5% | ||
| Q4 24 | — | 34.1% | ||
| Q3 24 | -136.4% | 37.8% | ||
| Q2 24 | -182.2% | 29.7% | ||
| Q1 24 | -138.9% | 24.2% |
资本支出强度LABRDVT
| Q4 25 | — | 0.5% | ||
| Q3 25 | 4.5% | 0.8% | ||
| Q2 25 | 8.7% | 0.9% | ||
| Q1 25 | 12.4% | 0.2% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | 10.2% | 0.2% | ||
| Q2 24 | 8.6% | 0.3% | ||
| Q1 24 | 1.7% | 0.4% |
现金转化率LABRDVT
| Q4 25 | — | 2.38× | ||
| Q3 25 | — | 2.41× | ||
| Q2 25 | — | 2.79× | ||
| Q1 25 | — | 1.45× | ||
| Q4 24 | — | 7.75× | ||
| Q3 24 | — | 4.22× | ||
| Q2 24 | — | 2.17× | ||
| Q1 24 | — | 2.41× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
RDVT
暂无分部数据
